INTRODUCTION
Advanced pancreatic ductal adenocarcinoma (PDA) is a lethal disease.
(1) Most drugs tested in PDA clinical trials were selected on the basis of their activity in preclinical models, which is not generally predictive of clinical outcome. (2) Traditional preclinical models are cell lines cultivated in monolayers or xenografts derived from them. Cells cultured in plastic may undergo substantial changes that deviate from their originator tumor, as recently shown with lung cancer cell lines. (3) In addition, the stroma is underrepresented in these models. Several lines of evidence demonstrate that stroma has a role in cancer cell survival and metastases, particularly in pancreatic cancer. (4, 5) Not surprisingly, targeting the stroma has recently been proposed as a novel strategy to improve drug delivery and chemotherapy efficacy in PDA (6, 7) , and holds particular promise for this disease characterized by an intense desmoplastic reaction. (6, 8) Other preclinical models have been tested in PDA, including genetically engineered mouse models (GEMM). These models maintain an intact immune system and many are histologically akin to human pancreatic cancer, including a dense desmoplastic stroma. (9) However, the predictive value of GEMM for assessing efficacy of novel anticancer agents in the clinic has not been extensively tested. Their dependence on a few critical genetic lesions, such as KRAS, P53 and CDKN2A/P16, might not reflect the genetic diversity that exemplifies human PDA (10) and they failed to predict response to Ras inhibitors in one clinical trial. (11) Early passages of freshly generated xenografts are probably better candidates for mimicking the heterogeneity of the disease and might be better predictors of response. We have previously established a collection of 23, extensively characterized PDA xenografts under an anonymized exempt tissue protocol that is being used as a platform for drug screening and biomarker development. (12, 13) The initial tumor bank comprised of these PDA xenograft did not include annotated clinical data such as clinical drug response.
The primary goal of this prospective clinical trial was use freshly generated xenografts from patients with resectable PDA to determine the engraftment rate and dynamics of the process, 
MATERIAL AND METHODS

Patients eligibility
Patients with pancreatic masses suspicious of a diagnosis of PDA were enrolled, prior to surgery, in J0507, a Johns Hopkins University clinical trial (NCT00276744). Tissue samples of PDA not needed for diagnosis were xenografted into nude mice.
Eligibility criteria also included ECOG performance status 0-1, age older than 18 years, expected survival longer than 12 weeks, no prior treatment for PDA, and adequate liver, renal and bone marrow function (absolute neutrophil count ≥ 1500/uL, platelets ≥ 100000/uL, hemoglobin ≥ 9 g/dL, serum creatinin ≤2 mg/dL, bilirubin ≤2 mg/dL, ALT, AST and alkaline phosphatase ≤5 times the upper limit of normal). The study was approved by the Johns Hopkins University institutional review board.
Xenografts
PDA tumor specimens from resected patients were implanted subcutaneously on each flank of five-to six-week old athymic nude mice and expanded as previously described.(12)
Treatment
When tumors reached ≈200mm 
SMAD4 and ALDH staining
Immunolabeling was performed on Bond-Leica autostainer (Leica Microsystems, Bannockburn, IL.) using a standard immunohistochemistry protocol (supplementary Methods).
Microarray Gene Expression
Primary tumors were profiled when possible using Affymetrix U133 Plus 2.0 GeneChip arrays (Affymetrix, Santa Clara, CA) in duplicates. In four patients primary tumors (F0) and paired samples from F5 (passage 5) and F10 (passage 10) were profiled. Sample preparation and processing were performed as described in the Affymetrix GeneChip Expression Analysis Manual (Affymetrix, Inc.). The gene expression data will be deposited at the NCBI GEO.
GSEA
Gene set enrichment analysis was performed using GSEA software, Version 2.0.1, obtained from the Broad Institute. (14) Gene set permutations were done 1000 times for each analysis.
The nominal P value and normalized enrichment score (NES) were used to rank the pathways enriched in each phenotype. We used 199 pathways defined by the Kyoto Encyclopedia of Genes and Genomes (KEGG) database as the gene set in this study. One hundred fifty-seven gene sets passed the gene set size filter criteria (min=10, max=500).
Statistical analysis
Research. were eligible to have their tumors xenografted into nude mice. These were patients with resected PDA who had not received neoadjuvant treatment. Of these 85, 69 were xenografted. The flow chart describes the reasons why patients could not be xenografted.
Forty-two of the 69 implanted cancers engrafted for an engraftment rate of 61%. Table 1 summarizes the principal clinical characteristics of patients and supplementary Table 1 lists detailed information regarding tumor stage, treatment, the xenograft generated from these patients and the principal biological information available from these tumors. This collection of well annotated PDA xenografts can form the basis of drug screening and biomarker development.
Biological Characteristics of Engrafted Tumors
To determine biological features associated with a higher rate of engraftment, we first estimated whether the proportion of tumor initiating cells (TICs), determined by the expression of ALDH, was related to a higher engraftment rate. Our group recently showed a correlation between the tumor initiating compartment and PDA and the expression of this intracellular enzyme.(16) However, we found no differences in the expression of ALDH in carcinomas that engrafted in mice compared to those that did not (data not shown).
We examined SMAD4 alterations to see if they were associated with a higher take rate in the mouse. The primary cancers from 58 of the 69 xenografted patients were analyzed and SMAD4 status was determined by Smad4 immunolabeling patterns, a strong marker of SMAD4 genetic status.(17, 18) The incidence of Smad4 protein loss was statistically higher in engrafted than in non-engrafted patients (67 vs. 36%, p=0.024) (Figure 2A ). We also show that Smad4 loss was not a marker of tumor grade given the fact that Smad4 might be deleted in low-grade tumors while preserved in poorly differentiated ones ( Figure 2B ).
Research. To explore further previous work from our group showing that SMAD4-mutant PDAs have a higher metastatic potential (18), we examined the presence of a metastasis-associated gene signature developed by Ramaswamy et al. (19) This gene-signature contains seventeen genes that were identified by comparing adenocarcinoma metastases from multiple tumor types to unmatched primary adenocarcinomas. In this analysis, we used the gene expression profiles from four primary tumors and two different passages of their matching xenografts.
We found that five out of eight genes from the gene signature of metastatic adenocarcinoma (SNRPF, EIF4E2, HNRPAB, DHPS, and PTTG1) were also upregulated in the xenografts compared to their counterpart primary tumors (Figure 3) . Additionally, four out of the nine genes that were downregulated in this gene signature were also downregulated in xenografts versus in primary tumors (F0).
Engrafted patients had poorer overall survival
Because cancers that successfully engrafted putatively have a higher metastatic potential, we investigated the prognostic role of engraftment in addition to other well known prognostic factors. We conducted a univariate analysis to determine impact on survival (supplementary table 2) and found that Smad4 status, tumor size ≥ 3.5cm, positive margins, no adjuvant treatment and ability to engraft were associated with shorter survival. In contrast, only tumor engraftment (p < 0.006) and adjuvant therapy (p<0.008) were significant predictors of shorter survival in the multivariate analysis. The median survival for engrafted patients was 299 days (95% CI 230 to 369 days), whereas the median survival for patients whose cancers failed to engraft has not been reached (>800 days). Patients whose cancers failed to engraft had a 81% reduction in the risk of death [HR=0.19, 95% CI (0.060, 0.632)] (supplementary Table 3 and Figure 4 ). As PDA patients typically die of metastatic disease, this finding is consistent with the Smad4 status and metastatic signature of engrafted cancers.
Research. 
Gene set enrichment analysis (GSEA) identified upregulation of stromal and Notch pathways in patients resistant to gemcitabine GSEA was used to investigate gene pathways that might be involved in resistance to gemcitabine using the gene expression profiles from primary tumors from patients treated with gemcitabine (supplementary Table 1 ). GSEA provides statistical measurements for the gene pathways that are enriched when gene expression profiles from two different phenotypes are compared (i.e., sensitive versus resistance to gemcitabine). At baseline, 79
and 76 pathways were upregulated in patients sensitive and resistant to gemcitabine, respectively. Gemcitabine-resistant tumors showed enrichment in gene pathways related to stroma (ECM receptor interaction, focal adhesion, cell communication, GAP junction, cell adhesion molecules) and stem cells (Notch signaling pathways) (supplementary Table 4 ).
Gemcitabine-sensitive tumors demonstrated upregulation of cell cycle and pyrimidine pathways (supplementary Table 5 ). Overall, these results suggest that coordinated overexpression of genes in stromal and Notch signaling pathways may confer resistance to gemcitabine.
Prediction of Clinical Outcome with Gemcitabine.
A xenograft was successfully developed in 23 patients who were clinically treated with gemcitabine. In the 7 of 23 patients for whom gemcitabine was used to treat metastatic disease, the response of the xenografted cancers to gemcitabine correctly predicted longer time to progression. In patients whose xenografts were sensitive to gemcitabine, the median time to progression was 80 vs. 46 days (log-rank p=0.037). Gemcitabine was administered in the adjuvant setting to 16 patients as part of varied complex multimodality regimens, precluding correlation between activity in the preclinical model with clinical outcome.
Anecdotally, however, one patient with a T3N1M0 cancer had a rather long disease-free survival after surgery and 6 cycles of conventional gemcitabine (1,203 days) but that patient's xenograft was resistant to gemcitabine. To gain further insight into this finding we performed an orthotopic implantation of the patient's tumor and observed that, in contrast to the subcutaneously implanted tumor, the orthotopic model was exquisitely sensitive to gemcitabine. In fact, the primary patient tumor and orthotopically implanted tumor had a similar gemcitabine response signature but diverse from the subcutaneously implanted tumor (supplementary Figure 1) . Moreover, while a desmoplastic reaction was present in the orthotopic model, it was significantly decreased in the subcutaneous xenograft (supplementary Figure 2) . Although this discrepancy was only observed in one patient, the evidence above suggest that orthotopic models may be better predictors of response in this disease.
tumors engraft are more likely to have metastatic disease. This is consistent with evidence from different disease types showing that engraftment is a marker of poor prognosis. (24, 25) Several lines of evidence suggest that the stroma plays an important role in the pathophysiology of cancer. Enrichment of stroma-related genes was observed in the progression from preinvasive disease to invasive gastrointestinal cancers. (26) This mechanism is not disease specific as mesenchymal stem cells within the stroma promote breast cancer growth and metastases. (27) Moreover, shifting towards a stromal phenotype is an intrinsic property of chemotherapy-resistant tumors.(28) An additional finding in our work was that stromal pathways were enriched in gemcitabine-resistant patients. We acknowledge that the number of samples included in the gene expression analysis was low to draw definitive conclusions (supplementary Table 1 ), however, this finding needs to be examined in the context of earlier works showing that stromal depletion may increase tumor permeability to gemcitabine and result in increased drug activity.(6, 7) A phase III trial is testing this "stromal collapse" strategy based on promising activity in the phase I setting. (29) The work presented here also augments information from previous preclinical models by developing tumors from clinically well-annotated cases. For many of these tumors, there is significant information available from ¨omics¨ technologies, including global exonic sequencing.(10) This is a unique platform for performing additional research in PDA, although the development of these platforms has not been limited to PDA. Recently, several papers have reported similar efforts in other diseases such as lung cancer, melanoma and breast cancer. (24, 30, 31) It is anticipated that these models will progressively become more utilized in early drug development discovery.
A fundamental question that must be answered to justify using freshly generated xenograft platforms for drug development is whether findings in the model correlate with clinical findings. Our first attempt to see if such a correlation existed was analyzing the results of adjuvant treatment. However, most patients included in this series had been treated with complex multimodality treatments that were impossible to replicate in a murine model (supplementary Table 1 ). In retrospect, it became apparent that the ability to appropriately assess correlations between the model and clinical responses in patients rested upon protocol-guided treatments. In the group of patients who received gemcitabine in a setting of advanced cancer, the time to treatment failure was longer in patients whose xenografts responded better to gemcitabine. A difficulty we also encountered was the lack of efficacy of gemcitabine in these xenografts and, indeed, as borne out by applying RECIST criteria to the T/C data and finding that not a single case reached the 30% partial response mark. This lack of response highlights the major issue in PDA treatment, which is the lack of minimally effective treatments. While overall these data are encouraging, additional work is needed to properly determine the predictive capabilities of these models. This point is illustrated by the potentially better predictive power of orthotopic implantation versus subcutaneous implantation.
In summary, we have developed and characterized a set of 42 PDA engrafted xenografts with annotated clinical information. Interestingly, successfully engrafted tumors are more likely to lack Smad4 and show a gene expression profile similar to cancer metastasis, which might explain the finding that these patients have a poorer prognosis. The stromal compartment has a putative role in resistance to gemcitabine. Despite the limitations in the number of patients and the overall lack of efficacy of gemcitabine treatment, the model seems to be predictive of response to gemcitabine in the metastatic setting. Given the complexities of generating these models and testing drugs in real time, it is unlikely that this approach will be broadly applicable to personalized cancer treatment, at least in PDA with its rapid clinical course and very few effective agents to address this refractory tumor. Moreover, our findings suggest that host microenviroments are better mimicked by orthotopic models. Although our data is limited to one patient, it suggest that orthotopic xenografts may be better predictors of response.
Additional work is needed to continue developing and exploring the role of freshly generated xenografts in cancer research. (F10). We tested a gene expression signature from metastatic adenocarcinoma and found that our xenografts were enriched in this metastatic gene signature. . Waterfall plot with gemcitabine activity in xenografts. We applied RECIST criteria to T/C to define sensitivity/resistance. We reduced the threshold of sensitivity to -15% in order to have sensitive xenografts, since none of them had a T/C <-30%. Green bars represent sensitive cases (T/C<-15%), gray bars represent stable disease (T/C -15 to 20%) and red bars represent progressive disease (T/C >20%)
